Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$75.1M Buy
563,367
+90,406
+19% +$10.2M 0.99% 5
2026
Q1
$52.7M Sell
472,961
-34,920
-7% -$4.13M 0.68% 5
2025
Q4
$68.5M Sell
507,881
-90,050
-15% -$9.83M 1.02% 7
2025
Q3
$50.8M Sell
597,931
-272,507
-31% -$16.7M 0.74% 10
2025
Q2
$6.66M Buy
870,438
+299,770
+53% +$1.95M 0.13% 221
2025
Q1
$3.57M Buy
570,668
+163,765
+40% +$1.11M 0.09% 291
2024
Q4
$2.98M Buy
+406,903
New +$3.75M 0.07% 354

Other funds holding ABVX

Boothbay Fund Management's ABVX Position: Q2 2026 in Review

Boothbay Fund Management increased its Abivax (ABVX) stake by 19% in Q2 2026, buying an estimated $10.2M and bringing the position to 563,367 shares worth $75.1M. The position accounts for 0.99% of the portfolio, ranked #5.

Boothbay Fund Management first reported a position in ABVX in Q4 2024 and has held it in 7 quarters since. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Boothbay Fund Management held 563,367 shares of Abivax worth $75.1M as of Q2 2026.
  • Boothbay Fund Management bought 90,406 Abivax shares in Q2 2026, an estimated $10.2M.
  • Abivax made up 0.99% of Boothbay Fund Management's portfolio in Q2 2026, its #5 holding.
  • Boothbay Fund Management first reported a position in Abivax in Q4 2024 and has held it in 7 quarters since.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.